$BBIO insider trading
Over the last 12 months, BridgeBio Pharma insiders reported no purchases and 38 sales totaling $118.8M across SEC Form 4 filings. 89% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $118.8M 38 events
- Events · 12m
- 38 Form 4 filings, grouped
- Insiders · 12m
- 10 distinct reporters
- 10b5-1 share
- 89% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 10,000 | $84.03 | $840K | -1.9% | plan · 3 tranches · indirect |
| Aug 18, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 34,980 | $82.53 | $2.9M | -12.6% | plan · 4 tranches |
| Jul 30, 2026 | Apuli MaricelChief Accounting Officer · O | ▼ Sale | 2,000 | $80.06 | $160K | -1.5% | plan |
| Jul 9, 2026 | Ellis AndreaD | ▼ Sale | 17,167 | $84 | $1.4M | -43.2% | plan |
| Jul 9, 2026 | Cook Jennifer E.D | ▼ Sale | 148,589 | $88.54 | $13.2M | -94.7% | plan · 2 tranches |
| Jun 24, 2026 | Cook Jennifer E.D | ▼ Sale | 39,363 | $69.92 | $2.8M | -82.4% | plan · 2 tranches |
| Jun 23, 2026 | Valantine HannahD | ▼ Sale | 5,004 | $68.25 | $342K | -35.1% | plan · 2 tranches |
| Jun 15, 2026 | Cook Jennifer E.D | ▼ Sale | 90,240 | $66.62 | $6.0M | -93.2% | plan · 2 tranches |
| Jun 5, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $67.67 | $5.4M | -1.8% | plan · 14 tranches · indirect |
| May 21, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 2,256 | $67.57 | $152K | -0.8% | plan |
| May 8, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $67.4 | $5.4M | -1.8% | plan · 12 tranches · indirect |
| Apr 30, 2026 | Apuli MaricelChief Accounting Officer · O | ▼ Sale | 2,000 | $71.58 | $143K | -1.5% | plan |
| Apr 10, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $74.61 | $6.0M | -1.8% | plan · 8 tranches · indirect |
| Mar 13, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $68.76 | $5.5M | -1.8% | plan · 10 tranches · indirect |
| Mar 10, 2026 | Valantine HannahD | ▼ Sale | 8,671 | $72 | $624K | -53.7% | plan |
| Mar 4, 2026 | Ellis AndreaD | ▼ Sale | 64,921 | $64.87 | $4.2M | -77.7% | plan |
| Feb 27, 2026 | Valantine HannahD | ▼ Sale | 25,484 | $67.41 | $1.7M | -77.3% | plan · 2 tranches |
| Feb 26, 2026 | Apuli MaricelChief Accounting Officer · O | ▼ Sale | 2,000 | $66 | $132K | -1.6% | plan |
| Feb 19, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 28,053 | $71.39 | $2.0M | -10.7% | plan · 3 tranches |
| Feb 17, 2026 | Apuli MaricelChief Accounting Officer · O | ▼ Sale | 510 | $74.31 | $38K | -0.4% | plan |
| Feb 17, 2026 | Trimarchi ThomasPresident and CFO · O | ▼ Sale | 13,600 | $74.72 | $1.0M | -3.9% | plan · 2 tranches |
| Feb 17, 2026 | Scott Randal W.D | ▼ Sale | 10,000 | $75.46 | $755K | -46.3% | plan · 3 tranches |
| Feb 11, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $71.86 | $5.7M | -1.8% | plan · 12 tranches · indirect |
| Jan 9, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $75.54 | $6.0M | -1.7% | plan · 14 tranches · indirect |
| Dec 15, 2025 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 30,011 | $74.64 | $2.2M | -11.6% | plan · 2 tranches |
| Dec 8, 2025 | Apuli MaricelChief Accounting Officer · O | ▼ Sale | 2,000 | $74.26 | $149K | -1.5% | plan |
| Dec 5, 2025 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $73.86 | $5.9M | -1.7% | plan · 10 tranches · indirect |
| Nov 20, 2025 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 26,156 | $65.84 | $1.7M | -10.3% | plan · 3 tranches |
| Nov 18, 2025 | Lo AndrewD | ▼ Sale | 55,000 | $65.69 | $3.6M | -52.1% | 2 tranches · indirect |
| Nov 17, 2025 | Lo AndrewD | ▼ Sale | 40,599 | $66.67 | $2.7M | -74.2% | 2 tranches |
| Nov 17, 2025 | Scott Randal W.D | ▼ Sale | 10,000 | $66.65 | $666K | -46.3% | plan · 2 tranches |
| Nov 17, 2025 | Trimarchi ThomasPresident and CFO · O | ▼ Sale | 16,934 | $66.46 | $1.1M | -4.2% | plan · 2 tranches |
| Nov 12, 2025 | Valantine HannahD | ▼ Sale | 25,484 | $66.07 | $1.7M | -77.3% | — |
| Nov 7, 2025 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $62.29 | $5.0M | -9.1% | plan · 12 tranches · indirect |
| Nov 6, 2025 | DANIELS RONALD JD | ▼ Sale | 61,031 | $63.72 | $3.9M | -78.2% | — |
| Oct 29, 2025 | MCCORMICK FRANKD | ▼ Sale | 198,359 | $66.58 | $13.2M | -22.6% | plan · 5 tranches · indirect |
| Oct 27, 2025 | MCCORMICK FRANKD | ▼ Sale | 1,641 | $65 | $107K | -0.2% | plan · indirect |
| Oct 9, 2025 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $54.79 | $4.4M | -8.7% | plan · 6 tranches · indirect |
| Sep 5, 2025 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $52.2 | $4.2M | -8.4% | plan · 10 tranches · indirect |
| Sep 5, 2025 | MCCORMICK FRANKD | ▼ Sale | 74,000 | $53.16 | $3.9M | -47.1% | — |
| Aug 21, 2025 | Trimarchi ThomasPresident and CFO · O | ▼ Sale | 42,237 | $49.48 | $2.1M | -9.1% | — |
| Aug 20, 2025 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 26,156 | $48.82 | $1.3M | -10.5% | plan · 2 tranches |
| Aug 18, 2025 | Trimarchi ThomasPresident and CFO · O | ▼ Sale | 17,353 | $50.23 | $872K | -3.6% | plan · 2 tranches |
| Aug 11, 2025 | HOMCY CHARLES JD | ▼ Sale | 300,000 | $46.37 | $13.9M | -24.7% | plan · 3 tranches |
| Aug 8, 2025 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $45.84 | $3.7M | -8% | plan · 8 tranches · indirect |
| Aug 7, 2025 | Apuli MaricelChief Accounting Officer · O | ▼ Sale | 1,000 | $45.44 | $45K | -0.7% | — |
Every $BBIO filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? BridgeBio Pharma filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BBIO feed.